Bausch Health Has Full Plate While Trimming Debt, Setting Table For Bausch + Lomb Separation
With Decision Pending On Spinout Method, SEC Form For IPO Filed
Bausch Health says it’s continuing a recovery from the disaster previous management left, when the firm operated as Valeant Pharmaceuticals, even though it reported a $595m net loss for Q2. “We've been trying to solve this debt issue for the company,” says CEO Joseph Papa.
You may also be interested in...
Canadian firm reports Bausch + Lomb full-year and fourth-quarter revenue growth earnings as preparations continue to divest the business. Consumer health led Bausch + Lomb’s segments.
J&J takes same approach GSK, Pfizer, Merck & Co, Merck and Novartis have with their consumer health businesses, Bausch Health is starting and Sanofi says it will.
Canadian firm plans to separate Solta first, with an IPO in December or January, and at least 30 days later offer shares in Bausch + Lomb. Order of IPOs could change, though.